#United States #New York #Securities Fraud #Pomerantz Law Firm #Capricor Therapeutics

Investor Alert: Pomerantz Law Firm's Investigation of Capricor Therapeutics

On June 7, 2025, the Pomerantz Law Firm announced it is initiating an investigation into potential claims on behalf of investors who have invested in Capricor Therapeutics, Inc. (NASDAQ: CAPR). This firm specializes in corporate securities and has a longstanding history of handling class action lawsuits. Investors who wish to raise their concerns or join the investigation are encouraged to contact Danielle Peyton, who is available at [email protected] or via phone at 646-581-9980, ext. 7980.

Background on Capricor Therapeutics

Capricor Therapeutics is known for its pursuit of pioneering treatments, particularly in the context of serious diseases such as Duchenne muscular dystrophy (DMD). Notably, the company is seeking full approval for deramiocel, a cell therapy aimed at tackling cardiomyopathy associated with DMD. This experimental treatment holds considerable promise for individuals diagnosed with the condition.

Recent Events Leading to Investigation

The recent plunge in Capricor's stock price offers the backdrop to Pomerantz's inquiry. On May 5, 2025, the company publicized that it had completed a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) regarding deramiocel. This announcement was met with a significant market reaction; Capricor's stock price fell dramatically, dropping $3.00, approximately 29.13%, closing at $7.30 per share the following day. The investigation by Pomerantz centers around whether any of the company's officers or directors have engaged in unlawful practices that could fall under the umbrella of securities fraud, potentially impacting investors adversely.

Pomerantz Law Firm: A Legacy of Advocacy

The Pomerantz Law Firm, established over 85 years ago, is widely recognized for its role in pioneering securities class actions. Its founder, Abraham L. Pomerantz, is referred to as the dean of the class action bar. Under this legacy, the firm has continued to champion the rights of investors harmed by securities fraud and breaches of fiduciary duty. The firm has successfully recouped millions in damages for class members, reinforcing its commitment to justice in the field of securities law.

What Investors Can Do

Investors in Capricor Therapeutics should closely monitor any developments or disclosures made by the company during this sensitive time. Those may wish to consider participating in the ongoing investigation either to safeguard their interests or to explore any potential claims they may wish to file. By doing so, they may recover losses incurred from recent market fluctuations related to Capricor's stock. Those with concerns or inquiries will find that reaching out to Pomerantz directly is the most effective means of pressing forward.

Conclusion

With the Pomerantz Law Firm investigating the implications of Capricor's recent activities, including a sharp decline in stock value and potential SEC violations, investors are aptly advised to stay informed. Whether contemplating legal action or wanting to understand their standing, engaging with a reputed legal firm like Pomerantz can offer both insight and possible routes for recourse in the event of proven wrongdoing. As developments unfold, keeping informed will be key to navigating this unpredictable environment surrounding Capricor Therapeutics.